Specials Laboratory to supply clinical trials service to UK hospitals

Published: 29-Mar-2010

New service aims to meet the product manufacturing needs of NHS-based clinical trials

Hospitals across the UK will be able to take advantage of a new service aimed at meeting the product manufacturing needs of NHS-based clinical trials.

The Specials Laboratory, based in Northumberland, is to specialise in the supply of non-sterile products for use in small-scale clinical studies direct to hospitals after the specialist firm was licensed for the manufacture of investigational medicinal products (IMPs).

The new IMP service will assist clinical trial pharmacists and technicians, university medical schools and research doctors.

Operating from three MHRA-approved facilities, the company complies with current Good Manufacturing Practice (cGMP) and provides in-house Quality Person (QP) release, which will ensure products delivered to hospitals will be made to the highest possible quality standards.

‘Our quality-led manufacturing heritage allows us to produce virtually any non-sterile dosage form,’ said Robert Sludden, Quality and Technical Services Manager at The Specials Laboratory.

‘The company is also able to offer customers an experienced technical team that includes several pharmacists, senior pharmacy technicians and QPs – many with an extensive NHS background.’

With more hospitals opting to subcontract their IMP manufacturing needs, The Specials Laboratory is looking to build relationships with relevant NHS departments by offering to be their outsourced manufacturing partner supplying products for smaller clinical trials.

‘Hospital departments will be able to source a wide range of products from The Specials Laboratory for their IMP manufacturing requirements, including oral liquids, capsules, sachets, ointments, creams, ear and nasal drops, enema solutions, suppositories and pessaries,' added Sludden.

Set-up over a decade ago, The Specials Laboratory employs around 130 people and is a leading UK manufacturer of unlicensed medicines, which are bespoke for individual patients and supplied to community and hospital pharmacists and doctors.

See more

You may also like

Manufacturing

PCCA buys the specials business and Arjun Products from UDG Healthcare for £23.5m

Read more
Deal includes The Specials Laboratory and Craig & Hayward in Northumberland, UK

Trending Articles

  1. Marchesini Group and AST announce strategic partnership to strengthen aseptic production capacity and expand global market presence Marchesini Group, a leader in pharmaceutical packaging machinery, and AST, a US leader in the drug product manufacturing industry, have entered a strategic partnership that combines the expertise, technologies, and global reach of two highly respected industry leaders
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Requalification as a strategic opportunity for sustainable pharmaceutical packaging Requalification is often viewed as a critical — albeit inconvenient — disruption in pharmaceutical operations, which is essential to ensure product quality, consistency and safety
  3. Dec Group teams up with Kolbelco Eco Solutions to launch mixer-type freeze dryer Developed to overcome the limitations of conventional shelf dryers, RHEOFREED offers a compact, GMP-compliant alternative for small-scale and full-scale pharmaceutical manufacturing
  4. BIA report highlights UK innovation and efficiency in global cell and gene therapy sector The report provides a comprehensive analysis of the UK's cell and gene therapy sector, focusing on the innovative technologies and strategic investments that are driving scale
  5. Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Manufacturing

PCCA buys the specials business and Arjun Products from UDG Healthcare for £23.5m

Deal includes The Specials Laboratory and Craig & Hayward in Northumberland, UK
Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Manufacturing

Cellevate achieves ISO 9001:2015 certification alongside GMP production processes in new cleanroom

The certification caps off a strong 2025 for the company, which now has a scalable foundation for expanding manufacturing capacity and implementing GMP-ready processes for commercial volumes
Drug Delivery

Zephyrus Innovations receives 510(k) clearance from FDA for VaporShield CSTD

With CSTDs now required in the US under USP<800> legislation, VaporShield is the first direct injection CSTD for subcutaneous and intramuscular administration
Manufacturing

LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener

Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
Dosage Forms

AI-engineered nasal spray could block flu and COVID-19

Researchers have successfully developed an intranasal antiviral platform using AI technology to overcome the existing limitations of interferon-lambda treatments, revealing a possible universal prevention platform for multiple respiratory viruses
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Subscribe now